Spatial variation in spring arrival patterns of Afro‐Palaearctic bird migration across Europe

Aim: Geographical patterns of migrant species arrival have been little studied, despite their relevance to global change responses. Here, we quantify continent-wide inter-specific variation in spatio-temporal patterns of spring arrival of 30 common migrant bird species and relate these to species characteristics and environmental conditions.Location: EuropeTime period: 2010-2019Major taxa studied: Birds, 30 speciesMethods: Using citizen science data from EuroBirdPortal, we modelled arrival phenology for 30 Afro-Palearctic migrant species across Europe to extract start and duration of species arrival at a 400 km square resolution. We related inter and intra-specific variation in arrival and duration to species characteristics and temperature at the start of the growing season (green-up) .Results: Spatial variation in start of arrival times indicates it took on average 1.6 days for the leading migratory front to move northwards by 100 km (range: 0.6—2.5 days). There was a major gradient in arrival phenology, from species which arrived earlier, least synchronously, in colder temperatures and progressed slowly northwards to species which arrived later, most synchronously and in warmer temperatures, and advanced quickly through Europe. The slow progress of early arrivers suggests that temperature limits their northward advance; this group included Aerial Insectivores and species wintering north of the Sahel. For the late arrivers, which included species wintering further south, seasonal resource availability in Africa may delay their arrival into Europe.Main conclusions: We found support for the green-wave hypothesis applying widely to migratory landbirds. Species arrival phenologies are linked to ecological differences between taxa, such as diet, and wintering location. Understanding these differences informs predictions of species’ sensitivity to global change. Publishing these arrival phenologies will facilitate further research and have additional conservation benefits such as informing designation of hunting seasons. Our methods are applicable to any taxa with repeated occurrence data across large scales. Key words: phenology, European-African migrants, bird migration, spring arrival, spatial variation, intraspecific and interspecific variation, EuroBirdPortal, citizen scientists, complete lists and casual record

Towards comprehensive assessment of mitral regurgitation using cardiovascular magnetic resonance

Cardiovascular magnetic resonance (CMR) is increasingly used to assess patients with mitral regurgitation. Its advantages include quantitative determination of ventricular volumes and function and the mitral regurgitant fraction, and in ischemic mitral regurgitation, regional myocardial function and viability. In addition to these, identification of leaflet prolapse or restriction is necessary when valve repair is contemplated. We describe a systematic approach to the evaluation of mitral regurgitation using CMR which we have used in 149 patients with varying etiologies and severity of regurgitation over a 15 month period

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries

Abstract Background Healthcare cannot achieve net-zero carbon without addressing operating theatres. The aim of this study was to prioritize feasible interventions to reduce the environmental impact of operating theatres. Methods This study adopted a four-phase Delphi consensus co-prioritization methodology. In phase 1, a systematic review of published interventions and global consultation of perioperative healthcare professionals were used to longlist interventions. In phase 2, iterative thematic analysis consolidated comparable interventions into a shortlist. In phase 3, the shortlist was co-prioritized based on patient and clinician views on acceptability, feasibility, and safety. In phase 4, ranked lists of interventions were presented by their relevance to high-income countries and low–middle-income countries. Results In phase 1, 43 interventions were identified, which had low uptake in practice according to 3042 professionals globally. In phase 2, a shortlist of 15 intervention domains was generated. In phase 3, interventions were deemed acceptable for more than 90 per cent of patients except for reducing general anaesthesia (84 per cent) and re-sterilization of ‘single-use’ consumables (86 per cent). In phase 4, the top three shortlisted interventions for high-income countries were: introducing recycling; reducing use of anaesthetic gases; and appropriate clinical waste processing. In phase 4, the top three shortlisted interventions for low–middle-income countries were: introducing reusable surgical devices; reducing use of consumables; and reducing the use of general anaesthesia. Conclusion This is a step toward environmentally sustainable operating environments with actionable interventions applicable to both high– and low–middle–income countries

Zeuxis: My Studio 015

This exhibition, which was featured in the Robert and Elaine Stein Galleries at Wright State University, featuring works by the artists of Zeuxis. This exhibition ran from January 15 to February 28, 2020. For this project, the artists of Zeuxis focused on their own studio spaces. This is to help grant insight into their working process, as the artist\u27s own working space is very often seen as insight into their work and sometimes even used as the subject of their work.https://corescholar.libraries.wright.edu/restein_exhibitions_all/1559/thumbnail.jp

Zeuxis: My Studio 009

This exhibition, which was featured in the Robert and Elaine Stein Galleries at Wright State University, featuring works by the artists of Zeuxis. This exhibition ran from January 15 to February 28, 2020. For this project, the artists of Zeuxis focused on their own studio spaces. This is to help grant insight into their working process, as the artist\u27s own working space is very often seen as insight into their work and sometimes even used as the subject of their work.https://corescholar.libraries.wright.edu/restein_exhibitions_all/1553/thumbnail.jp